Bone Therapeutics appoints directors | S&P Global Market Intelligence

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
PODCASTS
SEE ALL EPISODES
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
Webinar2024 Regulatory Reporting Horizon: what to expect and how to prepare
- 12/05/2023
- Live, Online
- 03:00 pm - 04:00 pm GMT | 10:00 am- 11:00 am EST
WebinarUnderstanding, Identifying, and Assessing Supplier Diversity
- 12/06/2023
- Live, Online
- 01:00 pm - 02:00 pm EST
Webinar2024 Regulatory Reporting Horizon: what to expect and how to prepare
- 12/05/2023
- Live, Online
- 03:00 pm - 04:00 pm GMT | 10:00 am- 11:00 am EST
PLATFORMS
OTHER PRODUCTS
- Research Online
- 451 Research
See All Product Logins

Bone Therapeutics appoints directors

Essential IR Insights Newsletter Fall - 2023

A Corporation Clearly Pinpoints Activist Investor Activity

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

29 May, 2017 | 06:49

Bone Therapeutics appoints directors

Author Vince Iral
Theme Healthcare & Pharmaceuticals

Bone Therapeutics SA appointed Steve Swinson and Damian Marron to its board.

The nonexecutive directors will succeed Jacques Reymann and Jean-Jacques Verdickt who are retiring.

Swinson led Medtronic International Ltd.'s spine and biologics division for Canada and Western Europe before joining Bone Therapeutics.

Marron is the former CEO of Agalimmune Ltd.